A recent study conducted by scientists at the Norwegian University of Science and Technology (NTNU) has uncovered alarming findings regarding a class of arthritis medications known as Janus kinase inhibitors (JAK inhibitors). These commonly prescribed anti-inflammatory drugs, used primarily for conditions such as rheumatoid arthritis, may unexpectedly weaken the body’s immune response against viruses, including COVID-19 and influenza.
The study revealed that JAK inhibitors could diminish the body’s natural defenses against viral infections. This is particularly concerning, as it may facilitate the spread of viruses like SARS-CoV-2 and influenza A within the body.
One of the most notable drugs examined, Baricitinib, has been shown to slow down the activity of specific genes responsible for combating viral infections. These genes act as a critical component of the body’s immune “security system.” When their function is compromised, the ability to detect and destroy viruses diminishes significantly.
Researchers conducted experiments on human cells sourced from the lungs, eyes, and brain, and also utilized lab-grown mini-organs, leveraging advanced gene analysis techniques to gauge the effects of these medications.
The lead author of the study, Erlend Ravlo, emphasized the need for caution among healthcare providers when prescribing these drugs, especially during viral outbreaks. Individuals with weakened immune systems may be particularly at risk from these unintended side effects.
Interestingly, while the side effects pose risks during active viral infections, the researchers noted that in controlled settings, such as in antiviral drug screenings or vaccine development, the ability to weaken immunity could aid in assessing treatment efficacy.
Healthcare professionals are being urged to carefully evaluate the risks versus benefits when prescribing JAK inhibitors, considering the current epidemiological context. The study advocates for further research into the long-term implications of these drugs and their interactions with viral infections, aiming to better inform clinical practices and patient care.
-Raja Aditya
